Shandong Lukang Shelile Pharmaceutical Co., Ltd.May 30, 2025

FDA 483 - Shandong Lukang Shelile Pharmaceutical Co., Ltd. - May 30, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Shandong Lukang Shelile Pharmaceutical Co., Ltd.

Record Details

Shandong Lukang Sheile Pharmaceutical Co., Ltd. in Zoucheng, China, received a Form 483 with two observations. The inspection revealed significant deficiencies in the firm's handling of Out-of-Specification (OOS) results, including inadequate investigations and unjustified root causes. Additionally, the Quality Unit's procedures for retain sample management were not adequately defined or followed.

Company: Shandong Lukang Shelile Pharmaceutical Co., Ltd.
Inspection Date: May 30, 2025
Product Type: Drugs
Office: Office of Inspections and Investigations
Person: Rajiv R. Srivastava (Consumer Safety Officer)

Open in Dashboard

ID · 17306efb-0e2e-4e3f-a743-d6cc407ded69